

BRIEF COMMUNICATION

## **LEPR polymorphisms and haplotypes in Mexican patients with colorectal cancer**

Miriam Partida<sup>1</sup>, Melva Gutiérrez<sup>2,3</sup>, María de la Luz Ayala<sup>2</sup>, Nelly Margarita Macías<sup>4</sup>, Carlos Rogelio Alvizo<sup>2</sup>, Jorge Peregrina<sup>5,6</sup>

<sup>1</sup> Departamento de Ciencias Médicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Puerto Vallarta, Jalisco, México

<sup>2</sup> Doctorado en Genética Humana, Instituto de Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México

<sup>3</sup> Departamento de Clínicas, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatlilán de Morelos, Jalisco, México

<sup>4</sup> Laboratorio de Genética Humana, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán, Jalisco, México

<sup>5</sup> Instituto de Fisiología Celular, Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Zapopán, Jalisco, México

<sup>6</sup> Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, México

**Introduction:** Obesity and colorectal cancer could be linked by adipocytokines, which are proteins associated with cell proliferation. High levels of the adipocytokine leptin promote the development of colorectal cancer through its receptor.

**Objective:** To determine the association between c.326A>G and c.668A>G *LEPR* gene polymorphisms and colorectal cancer.

**Materials and methods:** DNA was extracted from the peripheral blood of 147 patients with sporadic colorectal cancer and 134 healthy people. Genotypes were obtained by PCR-RFLP and the association was determined by the odds ratio (OR) test using the SPSS™, version 10.0, program. Haplotype frequencies and linkage disequilibrium were estimated by the Arlequin, version 3.5, software.

**Results:** Both polymorphisms were in Hardy-Weinberg equilibrium. Only the c.326A>G heterozygous genotype revealed an increased risk for colorectal cancer development (OR=1.81, 95% CI=1.04-3.16,  $p=0.04$ ). The AG haplotype showed a significant association with colorectal cancer (OR=0.58, 95% CI=0.35-0.96,  $p<0.03$ ). Linkage disequilibrium between the variants was only evident for the patients group ( $r^2=0.36$ ).

**Conclusion:** Our results suggest that AG individuals heterozygous for the c.326A>G *LEPR* variant have a higher risk of colorectal cancer development whereas the AG haplotype (c.326A/c.668G) has a protective effect in the Mexican population.

**Key words:** Receptors, leptin; colorectal neoplasms; polymorphism, genetic; haplotypes; odds ratio; Mexico.

### **Polimorfismos y haplotipos del gen *LEPR* en pacientes mexicanos con cáncer colorrectal**

**Introducción.** La relación entre la obesidad y el cáncer colorrectal podría estar dada por las adipocitocinas, proteínas asociadas con la proliferación celular. Los niveles elevados de la adipocitocina leptina promueven el desarrollo del cáncer colorrectal a través de su receptor.

**Objetivo.** Determinar la asociación de los polimorfismos c.326A>G y c.668A>G del gen *LEPR* con el cáncer colorrectal.

**Materiales y métodos.** A partir de sangre periférica, se extrajo el ADN de 147 pacientes con cáncer colorrectal esporádico y de 134 personas sanas. La genotipificación se hizo mediante PCR-RFLP y la asociación se determinó por la *odds ratio* (OR) en el programa SPSS™, versión 10.0. Las frecuencias haplotípicas y el desequilibrio de ligamiento se estimaron utilizando el programa Arlequin, versión 3.5.

**Resultados.** Ambos polimorfismos estaban en equilibrio de Hardy-Weinberg. Solo el genotipo heterocigoto c.326A>G reveló un mayor riesgo de desarrollar cáncer colorrectal (OR=1,81; IC<sub>95%</sub> 1,04-3,16;  $p=0,04$ ). El haplotipo AG mostró una asociación significativa con este cáncer (OR=0,58; IC<sub>95%</sub> 0,35-0,96;  $p<0,03$ ) y el desequilibrio de ligamiento entre las variantes fue evidente únicamente en el grupo de pacientes ( $r^2=0,36$ ).

**Conclusión.** Los resultados sugieren que los individuos heterocigotos con el haplotipo AG para la variante c.326A>G en el gen *LEPR* tenían un mayor riesgo de desarrollar cáncer colorrectal, en tanto que el haplotipo AG (c.326A/c.668G) tenía un efecto protector en la población mexicana.

**Palabras clave:** receptores de leptina; neoplasias colorrectales; polimorfismo genético; haplotipos; oportunidad relativa; México.

**Received:** 06/10/17

**Accepted:** 13/06/18

**Published:** 18/06/18

**Citation:**

Partida M, Gutiérrez M, Ayala ML, Macías NM, Alvizo CR, Peregrina J. *LEPR* polymorphisms and haplotypes in Mexican patients with colorectal cancer. *Biomédica*. 2019;39:205-11  
<https://doi.org/10.7705/biomedica.v39i1.4091>

**Corresponding author:**

Jorge Peregrina, Instituto de Fisiología Celular, Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Carretera Guadalajara-Nogales Km 15.5, predio las Agujas, Zapopán, Jalisco, México  
Telephone: (0152) 3777 1150  
psj15969@cucba.udg.mx

**Author contributions:**

Miriam Partida, Melva Gutiérrez and Jorge Peregrina: study conception and design, data collection and analysis  
Nelly Margarita Macías: data interpretation  
María de la Luz Ayala and Carlos Rogelio Alvizo: data analysis and interpretation  
All authors contributed to the writing of the manuscript.

**Funding:**

Universidad de Guadalajara.

**Conflict of interest**

The authors declare no conflict of interest.

Colorectal cancer is the second (in women) or third (in men) most common neoplasm worldwide. In México, colorectal cancer ranks fourth in both sexes (1). Environmental, genetic and epigenetic factors have been related to colorectal cancer development (2-4). Although obesity increases the risk of colorectal cancer by 1.5- to 2-fold (5) and 17.7% of the cases are ascribed to excess body mass (6), the cause of this association is not yet clear.

The relationship between colorectal cancer and obesity may reflect the impaired structure or function of adipocytokines, which are proteins that regulate cell proliferation, angiogenesis, and apoptosis (7). For instance, an increase in leptin appears to promote the development and progression of colorectal cancer (8).

The LEPR (*leptin receptor*) protein is encoded by a gene in the 1p31.3 locus (9). The *LEPR* polymorphisms c.326A>G (rs1137100) and c.668A>G (rs1137101) are located in exons 4 and 6, respectively. The former results in a conservative substitution of arginine for lysine in codon 109 (p.K109R) while the latter produces a non-conservative change of glutamine to arginine in codon 223 (p.Q223R) (10). This p.Q223R substitution occurs inside the region coding for the extracellular domain and could affect the interaction with leptin (11). Even if the impact of the LEPR pathway in C colorectal cancer is not yet clear, increased expression in tumor tissue has been related to proliferation and angiogenesis (12).

The objective of this study was to determine the association between c.326A>G and c.668A>G *LEPR* polymorphisms and colorectal cancer in Mexican patients.

## **Material and methods**

### ***Patients and controls***

The analysis included 147 patients diagnosed by histopathological and clinical criteria with sporadic colorectal cancer at the *Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"*. The group included 87 males and 60 females with an average age of 57 years (range: 20 to 69 years). The control group was integrated by 134 blood donors from the same hospital without a colorectal cancer diagnosis.

All subjects signed the informed consent. This study was approved by the ethics committee of *Centro Universitario de Los Altos, Universidad de Guadalajara* (CUA/CINV/PCIL-011/2009).

### ***DNA extraction***

We used the Miller method (13) combined with the DTAB-CTAB protocol (14) on each 5-ml sample of peripheral blood with EDTA added as an anticoagulant. DNA purity and concentration were determined by spectrophotometry.

### ***PCR-RFLP***

We searched for *LEPR* variants with a PCR-RFLP protocol according to predetermined conditions (15,16). For the c.326A>G variant, we used 5'-TTTCCACTGTTGCTTTTCGGA-3' forward and 5'-AAACTAAAGAATTTACTGTTGAAACAAATGGC-3' reverse primers under the following conditions: DNA initial denaturation for 5 min at 94°C; 40

cycles of 94°C for 45 s, annealing at 61.8°C for 45 s, extension at 72°C for 90s, and a final extension at 72°C for 10 min. We looked for the c.668A>G *LEPR* polymorphism using 5'-AAACTCAACGACACTCTCCTT-3' forward and 5'-TGAACGTACATTAGAGGTGA-3' reverse primers and amplification conditions similar to those described above except for an annealing temperature of 55°C.

For the single nucleotide polymorphism analysis, we used the restriction enzymes *HaeIII* for c.326A>G and *HpaII* for c.668A>G (both of which recognize the polymorphic G allele) for 16 hours. The assays were done in duplicate.

### Electrophoresis

DNA fragments were identified in 6% polyacrylamide gels stained with silver nitrate. Their sizes were 101, 70 and 31 bp for c.326A>G and 80, 58 and 22 bp for c.668A>G.

### Statistical analysis

Allelic and genotypic frequencies were determined by direct counting. The distribution of genotypes was tested for Hardy-Weinberg equilibrium using the  $\chi^2$  test. Haplotype frequencies and linkage disequilibrium values were calculated by the Arlequin, version 3.5, software (17). Linkage disequilibrium with  $r^2 > 0.3$  was considered to be significant (18). Intergroup differences were established by  $\chi^2$  or Fisher's exact test and the association was determined by the odds ratio (OR) in SPSS™, version 10.0.

## Results

### LEPR polymorphisms

Demographic and clinical data of CRC patients are listed in table 1. In the control group, both *LEPR* polymorphisms were in Hardy-Weinberg equilibrium ( $p > 0.05$ ). For methodological reasons, not all individuals were included in the analysis. The comparison between controls and colorectal cancer patients associated the AG genotype of c.326A>G to an increased risk for colorectal cancer (OR=1.81, 95% CI=1.04-3.16,  $p=0.04$ ) while no association was found for the c.668A>G polymorphism (table 2).

**Table 1.** Demographic data of colorectal cancer patients (n=147)

Variable	n (%)
Gender	
Female	60 (41)
Male	87 (59)
Diabetes	
Yes	28 (19)
No	102 (69)
Missing data	17 (12)
Smoking	
Yes	75 (51)
No	59 (40)
Missing data	13 (9)
Alcohol consumption	
Yes	70 (47.6)
No	60 (40.8)
Missing data	17 (11.6)

**Table 2.** Genotypes and allele frequencies of c.326 A>G and c.668A>G *LEPR* polymorphisms in controls and colorectal cancer patients

Gene <i>LEPR</i> SNP c.326 A>G	Control (N=100)		CRC (N=127)		OR (95% CI)	p*
	n	%	n	%		
Genotype						
AA	54	54	53	42	1.0 (Reference)	
AG	36	36	64	50	1.81 (1.04-3.16)	<b>0.04</b>
GG	10	10	10	8	1.02 (0.39-2.65)	0.97
Allele						
A	144	72	170	67	1.0 (Reference)	
G	56	28	84	33	1.27 (0.85-1.90)	0.25
SNP c (%) .668 A>G	Control n	CRC (%)	Control n	CRC (%)		
Genotype						
A	39	29	43	29	1.0 (Reference)	
AG	69	52	79	54	1.04 (0.61-1.78)	0.89
GG	26	19	25	17	0.87 (0.43-1.76)	0.70
Allele						
A	147	55	165	56	1.0 (Reference)	
G	121	45	129	44	0.95 (0.68-1.33)	0.76

CRC: Colorectal cancer; OR: Odds ratio; CI: Confidence interval.

\*Chi-square or Fisher's exact test; figure in bold corresponds to p&lt;0.05

### **LEPR haplotypes**

The haplotype AA was the most frequent in controls (93/194; 48%) and colorectal cancer patients (132/254; 52%). LD was only evident among the latter ( $r^2=0.36$ ). The AG haplotype showed a significant association with colorectal cancer (OR=0.58, CI=0.35-0.96, p<0.03) (table 3).

**Table 3.** Haplotype frequencies for c.326 A>G/c.668 A>G *LEPR* polymorphisms

Haplotype <i>LEPR</i> (c.326A>G/ c.668A>G)	Chromosomes				OR (95% CI)	p*
	Control (N=100)		CRC (N=127)			
	n	%	n	%		
AA	93	48	132	52	Reference	
AG	46	23.7	38	15	0.58 (0.35-0.96)	<b>0.03</b>
GA	11	5.6	13	5	0.83 (0.36-1.94)	0.6
GG	44	22.7	71	28	1.14 (0.72-1.80)	0.6

CRC: Colorectal cancer; OR: Odds ratio; CI: Confidence interval

\*Chi-square or Fisher's exact test; figure in bold corresponds to p&lt;0.05

### **Discussion**

Our finding of an increased risk of colorectal cancer in heterozygous AG individuals for the *LEPR* c.326A>G polymorphism compares with a similar association documented in Korean patients with gastric cancer (19). Regarding the same single nucleotide polymorphism (SNP), an increased risk (OR=1.64; 95%CI=1.10-2.45; p=0.016) for luminal A breast cancer was observed in GG patients (20) whereas the G allele was associated with prostate cancer mortality (hazard ratio=0.82; 95%CI=0.67-1.00; p=0.027) in another study (21). Moreover, this missense c.326A>G (p.K109R) variant was associated with increased birth weight in the Human Gene Mutation Database (HGMD-public: CM032948) (22). However, no association was found in other cancer studies (16,23,24).

Inasmuch as lysine (K) and arginine (R) are basic large-size amino acids (25), the Ensembl project— as predicted by SIFT and Polyphen— classified this variant as tolerable and benign (26). Yet, the higher propensity of lysine to post- translation modifications (methylation, ubiquitination, acetylation, phosphorylation, and sumoylation) indicates that its substitution could lead to protein structure alterations and increase colorectal cancer susceptibility (27).

The lack of association of the *LEPR* c.668A>G polymorphism with colorectal cancer in this and previous studies (11,28-31), and also documented in other neoplasms (16,23,32-37), probably reflects that the change of glutamine (Q), a polar amino acid of medium size, to arginine (R), a large-sized and basic amino acid, is harmless.

However, opposite results have been reported. In Caucasian women with breast cancer, the G allele was related to differentiation grade (OR=2.45, 95%CI 1.40–4.31) (38). Likewise, an increased risk for breast (39), oral (40), and lung (41) cancer development ascribed to the same variant has been proposed. Additionally, two meta-analyses revealed no association with cancer (42,43). These controversial results could be explained by the genetic structure of populations or the presence of additional variants modifying the *LEPR* gene.

The apparent protective effect of the AG haplotype disclosed in the present analysis (c.326A>G/c.668A>G) is consistent with the view that the accumulation of *LEPR* variants and gene interactions modulates colorectal cancer risk and development.

In conclusion, our results indicate that in the Mexican population, the AG genotype of the c.326A>G *LEPR* variant increases the risk of CRC, whereas the AG haplotype (c.326A/c.668G) protects against such tumors.

### Acknowledgments

We thank Horacio Rivera for the critical review of the manuscript. Carlos Rogelio Alvizo is a student in Human Genetics and was supported by a CONACyT fellowship.

### References

1. **Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.** GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Accessed on: July 4, 2017. Available from: <http://globocan.iarc.fr/Default.aspx>
2. **Obuch JC, Ahnen DJ.** Colorectal cancer: Genetics is changing everything. *Gastroenterol Clin North Am.* 2016;45:459-76. <https://doi.org/10.1016/j.gtc.2016.04.005>
3. **Chowdhury S, Roy HK.** The genetics and molecular biology of colonic neoplasia: Practical implications for the clinician. *Curr Opin Gastroenterol.* 2017;33:47-52. <https://doi.org/10.1097/MOG.0000000000000323>
4. **Rodríguez-Salas N, Domínguez G, Barderas R, Mendiola M, García-Albéniz X, Maurel J, et al.** Clinical relevance of colorectal cancer molecular subtypes. *Crit Rev Oncol Hematol.* 2017;109:9-19. <https://doi.org/10.1016/j.critrevonc.2016.11.007>
5. **Huang XF, Chen JZ.** Obesity, the PI3K/Akt signal pathway and colon cancer. *Obes Rev.* 2009;10:610-6. <https://doi.org/10.1111/j.1467-789X.2009.00607.x>
6. **Arnold M, Lam F, Ervik M, Soerjomataram I.** Cancer and obesity: Global burden of cancer attributable to excess weight. Lyon, France: International Agency for Research on Cancer; 2015. Accessed on: July 4, 2017. Available from: <http://gco.iarc.fr/obesity>
7. **Pischon T, Nothlings U, Boeing H.** Obesity and cancer. *Proc Nutr Soc.* 2008;67:128-45. <https://doi.org/10.1017/S0029665108006976>

8. **Schwartz B, Yehuda-Shnaidman E.** Putative role of adipose tissue in growth and metabolism of colon cancer cells. *Front Oncol.* 2014;4:1-7. <https://doi.org/10.3389/fonc.2014.00164>
9. **National Center for Biotechnology Information.** LEPR leptin receptor [*Homo sapiens* (human)]: Gene ID: 3953. National Center for Biotechnology Information. Accessed on: September 4, 2017. Available from: <http://www.ncbi.nlm.nih.gov/gene/3953>
10. **Chung WK, Power-Kehoe L, Chua M, Chu F, Aronne L, Huma Z, et al.** Exonic and intronic sequence variation in the human leptin receptor gene (*LEPR*). *Diabetes.* 1997;46:1509-11. <https://doi.org/10.2337/diab.46.9.1509>
11. **Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J, et al.** Genetic variation in adipokine genes and risk of colorectal cancer. *Eur J Endocrinol.* 2009;160:933-40. <https://doi.org/10.1530/EJE-09-0039>
12. **Milosevic VS, Vukmirovic FC, Krstic MS, Zindovic MM, J Stojanovic D, Jancic SA.** Involvement of leptin receptor expression in proliferation and neoangiogenesis in colorectal cancer. *J BUON.* 2015;20:100-8.
13. **Miller SA, Dykes DD, Polesky HF.** A simple salting out procedure for extracting DNA for human nucleated cells. *Nucleic Acids Res.* 1998;16:1215.
14. **Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P.** A fast method for high-quality genomic DNA extraction from whole human blood. *Biotechniques.* 1991;11:298-300, 302.
15. **Gotoda T, Manning BS, Goldstone AP, Imrie H, Evans AL, Strosberg AD, et al.** Leptin receptor gene variation and obesity: Lack of association in a white British male population. *Hum Mol Genet.* 1997;6:869-76. <https://doi.org/10.1093/hmg/6.6.869>
16. **Kote-Jarai Z, Singh R, Durocher F, Easton D, Edwards SM, Ardern-Jones A, et al.** Association between leptin receptor gene polymorphisms and early-onset prostate cancer. *BJU Int.* 2003;92:109-112. <https://doi.org/10.1046/j.1464-410X.2003.04272.x>
17. **Excoffier L, Lischer HE.** Arlequin suite, ver. 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. *Mol Ecol Resour.* 2010;10:564-7. <https://doi.org/10.1111/j.1755-0998.2010.02847.x>
18. **Ardlie KG, Kruglyak L, Seielstad M.** Patterns of linkage disequilibrium in the human genome. *Nat Rev Genet.* 2012;3:299-309. <https://doi.org/10.1038/nrg777>
19. **Kim EY, Chin HM, Park SM, Jeon HM, Chung WC, Paik CN, et al.** Susceptibility of gastric cancer according to leptin and leptin receptor gene polymorphisms in Korea. *J Korean Surg Soc.* 2012;83:7-13. <https://doi.org/10.4174/jkss.2012.83.1.7>
20. **Nyante SJ, Gammon MD, Kaufman JS, Bensen JT, Lin DY, Barnholtz-Sloan JS, et al.** Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes. *Breast Cancer Res Treat.* 2011;129:593-606. <https://doi.org/10.1007/s10549-011-1517-z>
21. **Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, et al.** Genetic variants in the *LEPR*, *CRY1*, *RNASEL*, *IL4*, and *ARVCF* genes are prognostic markers of prostate cancer-specific mortality. *Cancer Epidemiol Biomarkers Prev.* 2011;20:1928-36. <https://doi.org/10.1158/1055-9965.EPI-11-0236>
22. **Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al.** Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat.* 2003;21:577-81. <https://doi.org/10.1002/humu.10212>
23. **Doecke JD, Zhao ZZ, Stark MS, Green AC, Hayward NK, Montgomery GW, et al.** Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. *Cancer Epidemiol Biomarkers Prev.* 2008;17:1007-12. <https://doi.org/10.1158/1055-9965.EPI-08-0023>
24. **Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, et al.** Adipokine genes and prostate cancer risk. *Int J Cancer.* 2009;124:869-76. <https://doi.org/10.1002/ijc.24043>
25. **Betts MJ, Russell RB.** Amino acid properties and consequences of substitutions. In: Barnes MR, Gray IC, editors. *Bioinformatics for geneticists.* First edition. Chichester: John Wiley & Sons Ltd; 2003. p. 291-316.
26. **Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, et al.** The Ensembl gene annotation system. *Database.* 2016;2016:1-19. <https://doi.org/10.1093/database/baw093>

27. **Azevedo C, Saiardi A.** Why always lysine? The ongoing tale of one of the most modified amino acids. *Adv Biol Regul.* 2016;60:144-50. <https://doi.org/10.1016/j.jbior.2015.09.008>
28. **Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, et al.** Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev.* 2017;16:2697-703. <https://doi.org/10.1158/1055-9965.EPI-07-0467>
29. **Vasku A, Vokurka J, Vasku-Bienertová J.** Obesity-related genes variability in Czech patients with sporadic colorectal cancer: Preliminary results. *Int J Colorectal Dis.* 2009;24:289-94. <https://doi.org/10.1007/s00384-008-0553-6>
30. **Karimi K, Arkani M, Safaei A, Pourhoseingholi MA, Mohebbi SR, Fatemi SR, et al.** Association of leptin receptor gene Gln223Arg polymorphism with susceptibility to colorectal cancer. *Gastroenterol Hepatol Bed Bench.* 2011;4:192-8.
31. **Mahmoudi T, Farahani H, Nobakht H, Dabiri R, Zali MR.** Genetic variations in leptin and leptin receptor and susceptibility to colorectal cancer and obesity. *Iran J Cancer Prev.* 2016;9:e7013. <https://doi.org/10.17795/ijcp-7013>
32. **Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, et al.** Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev.* 2004;13:779-86.
33. **Willet EV, Skibola CF, Adamson P, Skibola DR, Morgan GJ, Smith MT, et al.** Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms. *Br J Cancer.* 2005;93:811-6. <https://doi.org/10.1038/sj.bjc.6602762>
34. **Woo HY, Park H, Ki CS, Park YL, Bae WG.** Relationships among serum leptin, leptin receptor gene polymorphisms, and breast cancer in Korea. *Cancer Lett.* 2006;237:137-42. <https://doi.org/10.1016/j.canlet.2005.05.041>
35. **Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, et al.** Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. *Cancer Detect Prev.* 2007;31:95-101. <https://doi.org/10.1016/j.cdp.2007.02.004>
36. **Skoczen S, Tomasiak PJ, Bik-Multanowski M, Surmiak M, Balwierz W, Pietrzyk JJ, et al.** Plasma levels of leptin and soluble leptin receptor and polymorphisms of leptin gene -18G > A and leptin receptor genes *K109R* and *Q223R*, in survivors of childhood acute lymphoblastic leukemia. *J Exp Clin Cancer Res.* 2011;30:64. <https://doi.org/10.1186/1756-9966-30-64>
37. **Kim KZ, Shin A, Lee YS, Kim SY, Kim Y, Lee ES.** Polymorphisms in adiposity-related genes are associated with age at menarche and menopause in breast cancer patients and healthy women. *Hum Reprod.* 2012;27:2193-200. <https://doi.org/10.1093/humrep/des147>
38. **Gu F, Kraft P, Rice M, Michels KB.** Leptin and leptin receptor genes in relation to premenopausal breast cancer incidence and grade in Caucasian women. *Breast Cancer Res Treat.* 2012;131:17-25. <https://doi.org/10.1007/s10549-011-1778-6>
39. **Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, Chouchane L.** Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. *BMC Cancer.* 2006;6:38-47. <https://doi.org/10.1186/1471-2407-6-38>
40. **Yapikakis C, Kechagiadakis M, Nkenke E, Serefoglou Z, Avgoustidis D, Vylliotis A, et al.** Association of leptin -2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer. *J Cancer Res Clin Oncol.* 2009;135:603-12. <https://doi.org/10.1007/s00432-008-0494-z>
41. **Li Y, Geng J, Wang Y, Lu Q, Du Y, Wang W, et al.** The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients. *J Cancer Res Clin Oncol.* 2012;138:311-6. <https://doi.org/10.1007/s00432-011-1098-6>
42. **Liu P, Shi H, Liu R, Yang Y, Yang Y, Huang C, et al.** Lack of association between LEPR Q223R polymorphisms and cancer susceptibility: Evidence from a meta-analysis. *J BUON.* 2014;19:855-62. <https://doi.org/10.3892/br.2014.326>
43. **Wang Y, Yang H, Gao H, Wang H.** The association between LEPR Q223R polymorphisms and breast cancer risk. *Breast Cancer Res Treat.* 2015;151:1-6. <https://doi.org/10.1007/s10549-015-3375-6>